Restriction Requirement

In the March 11, 2003 Office Action, the Examiner required restriction under 35 U.S.C. §121 of claims 1-75 to one of VIII Groups of inventions.

Applicants respectfully request that the Examiner withdraw the restriction requirement in view of applicants' October 24, 2001 Amendment canceling claims 1-75 and that the Examiner examine claims 76-81 on their merits.

Information Disclosure Statement

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants would like to direct the Examiner's attention to the three references which are listed on the attached form PTO/SB/08A-B (substitute for form 1449/PTO) (**Exhibit B**). The two U.S. patent references are attached hereto as **Exhibits 1-2**. The remaining reference (San Millan et al. 1995) listed on the attached forms was previously cited by the Patent Office during the prosecution of U.S. Serial No. 09/385,752, from which the subject application claims benefit under 35 U.S.C. §120. Accordingly, pursuant to 37 C.F.R. §1.98(d), a copy of this previously cited reference is not included with this Information Disclosure Statement.

Applicants are submitting the subject Information Disclosure Statement pursuant to 37 C.F.R. §1.97(b)(3) before the mailing of a first Office Action on the merits. Accordingly, no fee is deemed necessary in connection with the filing of this Information Disclosure Statement.

CONCLUSION

No fee is deemed necessary in connection with the filing of this Communication and Information Disclosure Statement. However, if any fee is required to preserve the pendency of the subject application, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 01-1785.

Respectfully submitted,

AMSTER, ROTHSTEIN & EBENSTEIN
Attorneys for Applicants
90 Park Avenue
New York, New York 10016
(212) 697-5995

Dated: March 24, 2003
New York, New York

By: _____
Craig J. Arnold
Registration No. 34,287
Alan D. Miller
Registration No. 42,889

76. A method of detecting the presence or absence of a mutation in the sequence of the *PKD2* gene, comprising the steps of:

(a) obtaining a polynucleotide sample from a subject;

(b) comparing the polynucleotide sample to a reference wild-type *PKD2* sequence; and

(c) determining the differences, if any, between the polynucleotide sample and the reference wild-type *PKD2* sequence, wherein the differences are mutations which comprise one or more deletion, insertion, point, or rearrangement mutations.

77. The method of Claim 76, wherein the subject is an embryo, fetus, newborn, infant, or adult.

78. The method of Claim 76, wherein the polynucleotide sample is DNA or RNA.

79. A method of detecting the presence or absence of a mutation in the sequence of the *PKD2* gene, comprising the steps of:

(a) obtaining a polynucleotide sample from a subject; and

(b) performing sequence analysis of the polynucleotide sample to detect the presence or absence of a mutation in the sequence of the *PKD2* gene of the subject, wherein the mutation comprises one or more deletion, insertion, point, or rearrangement mutations.

80. The method of Claim 79, wherein the subject is an embryo, fetus, newborn, infant, or adult.

81. The method of Claim 79, wherein the polynucleotide sample is DNA or RNA.